Invasive carcinoma of breast
Item
histologically confirmed invasive breast cancer;
boolean
C0853879 (UMLS CUI [1])
Status post Operative Surgical Procedures | Primary Lesion Removed
Item
post-surgery, primary lesion been removed;
boolean
C0231290 (UMLS CUI [1,1])
C0543467 (UMLS CUI [1,2])
C1402294 (UMLS CUI [2,1])
C0849355 (UMLS CUI [2,2])
Postmenopausal state | Premenopausal state Impending Ovarian Function Tests
Item
post-menopausal patients or pre-menopausal patients who will receive ovarian function suppression;
boolean
C0232970 (UMLS CUI [1])
C0232969 (UMLS CUI [2,1])
C0332190 (UMLS CUI [2,2])
C0029930 (UMLS CUI [2,3])
Estrogen receptor positive | Progesterone receptor positive
Item
histologically confirmed er and/or pr positive ;
boolean
C0279754 (UMLS CUI [1])
C0279759 (UMLS CUI [2])
Aromatase Inhibitors Adjuvant therapy
Item
receiving adjuvant ais therapy in the following one years;
boolean
C0593802 (UMLS CUI [1,1])
C0677850 (UMLS CUI [1,2])
White Blood Cell Count procedure | Platelet Count measurement
Item
leukocyte ≥ 3*10(9)/l; platelets ≥ 75*10(9)/l;
boolean
C0023508 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
serum glutamate oxaloacetate(ast/sgot) or serum glutamic-pyruvic transaminase(alt/sgpt) <2.5 times of upper limit of normal range;
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
Creatinine measurement, serum | Blood urea nitrogen measurement
Item
serum creatinine/blood urea nitrogen(bun) ≤ upper limit of normal (unl) range;
boolean
C0201976 (UMLS CUI [1])
C0005845 (UMLS CUI [2])
Informed Consent
Item
written informed consent according to the local ethics committee equirements;
boolean
C0021430 (UMLS CUI [1])
Secondary malignant neoplasm of female breast
Item
metastatic breast cancer;
boolean
C0346993 (UMLS CUI [1])
Hormone Therapy Neoadjuvant
Item
received neo-adjuvant endocrine therapy;
boolean
C0279025 (UMLS CUI [1,1])
C1298676 (UMLS CUI [1,2])
Fracture of pelvis | Metabolic Bone Disorder
Item
history of pelvic fracture or bone metabolic disease;
boolean
C0149531 (UMLS CUI [1])
C0005944 (UMLS CUI [2])
Pharmaceutical Preparations Interfering Bone metabolism
Item
received drugs interfering bone metabolism in the last 12 months;
boolean
C0013227 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0596204 (UMLS CUI [1,3])
Bone Mineral Density T score
Item
baseline bone mineral density: t < -2sd;
boolean
C0177804 (UMLS CUI [1,1])
C3854607 (UMLS CUI [1,2])
Primary tumor Other
Item
with other primary malignant disease;
boolean
C0677930 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Comorbidity Severe Influence Long-term Follow-up | Exception Malignant disease
Item
with severe non-malignant co-morbidity that will influence long-term follow up;
boolean
C0009488 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C4054723 (UMLS CUI [1,3])
C1517942 (UMLS CUI [1,4])
C1705847 (UMLS CUI [2,1])
C0442867 (UMLS CUI [2,2])
Severe allergy Investigational New Drugs
Item
known severe hypersensitivity to any drugs in this study;
boolean
C2945656 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])